Travere Therapeutics (TVTX) Operating Margin (2014 - 2026)
Travere Therapeutics (TVTX) reported Operating Margin of 29.02% for Q1 2026, up 2319.0% on a YoY basis from 1.2% in Q1 2025, and down 414.79% quarter-over-quarter from 9.22% in Q4 2025.
Travere Therapeutics (TVTX) Operating Margin (2014 - 2026) Analysis & Trends
Travere Therapeutics has reported Operating Margin for 13 years, with the latest figure at 29.02% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin rose 2319.0% year-over-year to 29.02%; the trailing twelve-month figure through Mar 2026 stood at 81.41% (up 16450.0% YoY), and the FY2025 full-year result was 675.53%, down 53665.0% from the prior year.
- Operating Margin for Q1 2026 stood at 29.02%, down from 9.22% in the prior quarter.
- The five-year high for Operating Margin was 62.33% in Q3 2025, with the low at 336.53% in Q1 2024.
- Historically, Operating Margin has averaged 171.83% across 5 years, with a median of 209.13% in 2023.
- Annual changes were most pronounced in 2022 — Operating Margin sank 34914 bps — and 2025, when it surged 28432 bps.
- Travere Therapeutics' Operating Margin stood at 295.52% in 2022, then climbed by 29 bps to 209.13% in 2023, then jumped by 61 bps to 81.21% in 2024, then surged by 111 bps to 9.22% in 2025, then plunged by 415 bps to 29.02% in 2026.
- The last three Operating Margin figures came in at 29.02% (Q1 2026), 9.22% (Q4 2025), and 62.33% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn | -29.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.02% |
| Dec 31, 2025 | 9.22% |
| Sep 30, 2025 | 62.33% |
| Jun 30, 2025 | -11.05% |
| Mar 31, 2025 | -52.21% |
| Dec 31, 2024 | -81.21% |
| Sep 30, 2024 | -89.27% |
| Jun 30, 2024 | -125.11% |
| Mar 31, 2024 | -336.53% |
| Dec 31, 2023 | -209.13% |
| Sep 30, 2023 | -249.59% |
| Jun 30, 2023 | -322.87% |
| Mar 31, 2023 | -315.23% |
| Dec 31, 2022 | -295.52% |
| Sep 30, 2022 | -294.23% |
| Jun 30, 2022 | -274.24% |
| Mar 31, 2022 | -307.45% |
| Dec 31, 2021 | 53.62% |
| Sep 30, 2021 | -57.66% |
| Jun 30, 2021 | -64.66% |